Cargando…

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA

BACKGROUND: Although antidepressants are commonly used in patients with schizophrenia, meta-analytic guidance on the efficacy and safety of antidepressant augmentation evaluated as a single clinical strategy in patients with insufficient response to antipsychotic monotherapy is missing. METHODS: Sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galling, Britta, Correll, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887390/ http://dx.doi.org/10.1093/schbul/sby016.508

Ejemplares similares

O11.5. EFFECTIVENESS OF COORDINATED SPECIALTY CARE FOR EARLY PSYCHOSIS
por: Galling, Britta, et al.
Publicado: (2018)

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA
por: McDonnell, David, et al.
Publicado: (2018)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018)

Clinical predictors of therapeutic response to antipsychotics in schizophrenia
por: Carbon, Maren, et al.
Publicado: (2014)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Antipsychotic agents: efficacy and safety in schizophrenia
por: de Araújo, Arão Nogueira, et al.
Publicado: (2012)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

PS78. Naturalistic, retrospective comparison between antidepressant therapy and atypical antipsychotic augmentation therapy for patients with major depressive disorder
por: Cho, Se Hoon, et al.
Publicado: (2016)

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies
por: Skuban, Aleksandar, et al.
Publicado: (2016)

S232. ALPHA7 NICOTINIC RECEPTOR AGONISTS REVERSE THE HYPERDOPAMINERGIC STATE IN THE MAM MODEL OF SCHIZOPHRENIA
por: Neves, Gilda, et al.
Publicado: (2018)

Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation
por: Loebel, Antony, et al.
Publicado: (2015)

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder
por: Wen, X.J., et al.
Publicado: (2014)

Factors associated with antipsychotic use in non-psychotic depressed patients: results from a clinical multicenter survey
por: Zhou, Jingjing, et al.
Publicado: (2022)

Mortality risk of antipsychotic augmentation for adult depression
por: Gerhard, Tobias, et al.
Publicado: (2020)

AB232. The aetiology and efficacy of the treatment of persistent and recurrent hemospermia
por: Xiao, Hengjun, et al.
Publicado: (2016)

O7.2. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION IN A CLINICAL COHORT
por: Rubio, Jose, et al.
Publicado: (2018)

Augmentation with antidepressants in schizophrenia treatment: benefit or risk
por: Mao, Ye-Meng, et al.
Publicado: (2015)

Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2023)

Adjunctive antidepressive pharmacotherapy in schizophrenia patients
por: Zink, M.
Publicado: (2021)

Antipsychotic treatment and cognitive function in patients with schizophrenia
por: Tumova, M. A., et al.
Publicado: (2023)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
por: Skonieczna-Żydecka, Karolina, et al.
Publicado: (2018)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
por: Medrano, R., et al.
Publicado: (2021)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

Antidepressant use and psychosis hospitalization in persons with schizophrenia
por: Puranen, A., et al.
Publicado: (2023)

232. Do Antibiotic Timeouts Improve Antibiotic Utilization?
por: Kinn, Patrick, et al.
Publicado: (2018)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

T234. BREAKTHROUGH ON ANTIPSYCHOTIC MAINTENANCE MEDICATION: A STUDY-LEVEL META-ANALYSIS AND META-REGRESSION ANALYSIS
por: Rubio, Jose, et al.
Publicado: (2018)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
por: Tiihonen, Jari, et al.
Publicado: (2019)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Characterization of “Responder” in patients with Treatment-Resistant Schizophrenia (TRS) treated with a new antipsychotic added to their current antipsychotic monotherapy
por: Anand, R., et al.
Publicado: (2023)

The Potential for Kratom as an Antidepressant and Antipsychotic
por: Johnson, Lindsay E., et al.
Publicado: (2020)

Antidepressants- and antipsychotics-induced hepatotoxicity
por: Todorović Vukotić, Nevena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ph5l2avu08c1873aqokuirqq32